The Galien Forum USA 2019

PANEL
2

Co-Chairs
Joel S. Marcus
Executive Chairman & Founder
Alexandria Real
Estate Equities, Inc./
Alexandria Venture Investments
Co-Founder
Alexandria Summit

Lynne Zydowsky, PhD
Chief Science Officer
Alexandria Real
Estate Equities, Inc./
Alexandria Venture Investments
President and Co-Founder
Alexandria Summit

Panel Intro

Can disruptive innovation positively impact healthcare costs?


Joel S. Marcus
Executive Chairman & Founder
Alexandria Real
Estate Equities, Inc./
Alexandria Venture Investments
Co-Founder
Alexandria Summit

Joel S. Marcus is the Executive Chairman and Founder of Alexandria Real Estate Equities, Inc. (NYSE:ARE), an urban office REIT uniquely focused on collaborative life science and technology campuses in AAA innovation cluster locations, including Greater Boston, San Francisco, New York City, San Diego, and Seattle. Mr. Marcus co-founded Alexandria in 1994 as a garage startup with $19 million in Series A capital. As CEO from March 1997 to April 2018, he led its growth into an S&P 500 company with an $18 billion total market capitalization. In 1996, he founded Alexandria Venture Investments, the company’s venture capital arm, to provide strategic investment capital to transformative life science and technology companies. In 2011, Mr. Marcus, together with Lynne Zydowsky, PhD, and Deeda Blair, co-founded the Alexandria Summit®, an invitation-only gathering that brings together the world’s foremost visionaries from the pharmaceutical, biotechnology, and technology industries; medical, academic, financial, and philanthropic institutions; advocacy groups; and government to exchange ideas and help shape future decisions about life science research and development and policy to tackle the most important global healthcare challenges and accelerate the discovery of cost-effective, lifesaving therapies. Mr. Marcus serves on the boards of several organizations, including Accelerator Life Science Partners and AgTech Accelerator, for which he was an original architect and co-founder, the 9/11 Memorial & Museum, the Emily Krzyzewski Center, Foundation for the National Institutes of health, Friends of Cancer Research, the Navy SEAL Foundation, the Partnership for New York City, the Robin hood Foundation, and The Scripps Research Institute.


Lynne Zydowsky, PhD
Chief Science Officer
Alexandria Real
Estate Equities, Inc./
Alexandria Venture Investments
President and Co-Founder
Alexandria Summit

Lynne Zydowsky, PhD, is President and Co-Founder of the Alexandria Summit and Chief Science Officer of Alexandria Real Estate Equities, Inc./Alexandria Venture Investments. She is an experienced executive in the life science industry who has been involved in the launching and building of several successful companies. She has played key roles in corporate development, operations, and finance. In 2003, she founded Zydowsky Consultants offering services to life science companies. Prior to that, Dr. Zydowsky was Co- Founder and Chief Operating Officer of Renovis, Inc. (now Evotec) and served as Vice President of Pharmaceutical Business Development at Exelixis, Inc., which she helped build from the ground up. In 2011, Dr. Zydowsky, together with Joel Marcus and Deeda Blair, co-founded the Alexandria Summit®, an invitation-only gathering that brings together the world’s foremost visionaries from the pharmaceutical, biotechnology, and technology industries; medical, academic, financial, and philanthropic institutions; advocacy groups; and government to exchange ideas and help shape future decisions about life science research and development and policy to tackle the most important global healthcare challenges and accelerate the discovery of cost-effective, lifesaving therapies. Dr. Zydowsky currently serves on the Board of Trustees for Butler University (since September 2016) and on the Discovery Council for Harvard Medical School (since August 2018), and is a member of the West Coast Board for the international non-profit buildOn. Dr. Zydowsky earned her PhD in Chemistry from The Ohio State University and was a National Institutes of health postdoctoral fellow in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. She has a BS in Pharmacy from Butler University.